These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20091627)

  • 1. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; Nijman HW
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007287. PubMed ID: 25229990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific active immunotherapy for ovarian cancer.
    Paijens ST; Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; de Bruyn M; Nijman HW
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD007287. PubMed ID: 30199097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Dickinson HO
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding.
    Tan YH; Lethaby A
    Cochrane Database Syst Rev; 2013 Nov; (11):CD010241. PubMed ID: 24234875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical cyclosporine for atopic keratoconjunctivitis.
    González-López JJ; López-Alcalde J; Morcillo Laiz R; Fernández Buenaga R; Rebolleda Fernández G
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009078. PubMed ID: 22972132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
    Cochrane Database Syst Rev; 2008 Oct; (4):CD006014. PubMed ID: 18843699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganoderma lucidum (Reishi mushroom) for cancer treatment.
    Jin X; Ruiz Beguerie J; Sze DM; Chan GC
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007731. PubMed ID: 22696372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.
    Clarke T; Galaal K; Bryant A; Naik R
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006119. PubMed ID: 25198378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
    Berek JS
    Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer.
    Medeiros LR; Rosa DD; Bozzetti MC; Rosa MI; Edelweiss MI; Stein AT; Zelmanowicz A; Ethur AB; Zanini RR
    Cochrane Database Syst Rev; 2008 Oct; (4):CD005344. PubMed ID: 18843688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific keynote: immunological therapy for ovarian cancer.
    Berek JS; Dorigo O; Schultes B; Nicodemus C
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S105-9; discussion S110-3. PubMed ID: 12586097
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer.
    Nicholson S; Bomphray CC; Thomas H; McIndoe A; Barton D; Gore M; George AJ
    Cancer Immunol Immunother; 2004 Sep; 53(9):809-16. PubMed ID: 15127236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.